10 questions answered from cited research · Plain language
Yes, ponatinib can help if your CML is resistant to other drugs, especially if you have the T315I mutation, but it has serious side effects like heart problems.
Read the full answer →Yes, imatinib significantly lowers TNF-alpha levels in CML patients, and persistent high levels are linked to poor treatment response.
Read the full answer →Yes, asciminib (Scemblix) was approved in 2024 for newly diagnosed Ph+ CML-CP, and nilotinib (Danziten) was also approved for this indication.
Read the full answer →Yes, specific gene changes in ABCB1 and ABCG2 can affect how much imatinib stays in your blood, leading to higher drug levels.
Read the full answer →Yes, a case report describes a 68-year-old woman with myeloid sarcoma relapse in the breast 6 years after initial nasal cavity presentation.
Read the full answer →Gram-negative bloodstream infections occur in about 27% of children with AML during induction chemotherapy, with high rates of multidrug resistance and significant mortality.
Read the full answer →Yes, a large meta-analysis identified new genetic risk loci for AML at 2p23.3, 1q23.3, 2q33.3, and 2p21, and confirmed known mutations in FLT3, NPM1, TP53, and other genes.
Read the full answer →The overall response rate for CPX-351 in therapy-related AML is approximately 47-61%, with complete response rates around 47-58%.
Read the full answer →Yes, Vanflyta (quizartinib) is FDA-approved for newly diagnosed FLT3-ITD-positive AML in adults, used with chemotherapy and as maintenance.
Read the full answer →Yes, CPX-351 improves survival in patients with AML and myelodysplasia-related changes compared to standard chemotherapy, especially in those with AML-MR subtype.
Read the full answer →